The Role of n-Butyl Levulinate in Pharmaceutical Synthesis
The pharmaceutical industry relies heavily on a consistent supply of high-quality chemical intermediates to drive innovation and produce life-saving medications. Among these, n-Butyl Levulinate (CAS 2052-15-5) stands out as a significant compound, frequently utilized in the intricate synthesis pathways of various Active Pharmaceutical Ingredients (APIs). Understanding its characteristics and how to reliably source it is crucial for any pharmaceutical manufacturer aiming for efficiency and product integrity.
n-Butyl Levulinate: A Cornerstone Intermediate
n-Butyl Levulinate, a clear yellow to orange-brown liquid, is chemically known as Pentanoic acid, 4-oxo-, butyl ester. Its molecular formula, C9H16O3, and molecular weight of 172.22, are fundamental identifiers for chemists. The compound's purity, typically exceeding 99%, is a critical factor for its application in pharmaceutical synthesis, where even trace impurities can significantly impact the final product's efficacy and safety. Its physical properties, such as a boiling point of 240.3 °C, are also important for process design and optimization.
In pharmaceutical manufacturing, n-Butyl Levulinate serves as a versatile building block. Its chemical structure, featuring a ketone and an ester group, allows for a wide range of reactions, including nucleophilic additions, esterifications, and cyclizations. These reactions are foundational in constructing complex molecular architectures that form the basis of many modern drugs. The ability to buy n-Butyl Levulinate of high purity ensures that these synthetic steps proceed predictably and yield the desired pharmaceutical compounds with high efficiency.
Sourcing Strategies for Pharmaceutical Buyers
For pharmaceutical companies, sourcing intermediates like n-Butyl Levulinate involves stringent vendor qualification. Key considerations include the supplier's adherence to Good Manufacturing Practices (GMP), the consistency of their product quality, their capacity to scale up production, and the reliability of their delivery schedules. Identifying a trusted manufacturer and supplier in China, for instance, can offer significant advantages in terms of cost-effectiveness and access to large volumes. Buyers often seek out suppliers who can provide comprehensive documentation, including Certificates of Analysis (CoAs) and technical support.
As a dedicated supplier of pharmaceutical intermediates, we pride ourselves on meeting these rigorous demands. Our n-Butyl Levulinate is produced under strict quality control measures to ensure it meets the ≥99% purity standard required by the pharmaceutical sector. We understand the critical nature of your supply chain and are equipped to provide consistent, high-volume deliveries. If you are looking to buy n-Butyl Levulinate for your API synthesis, we offer a reliable and cost-effective solution directly from our manufacturing base in China.
Ensuring Quality and Availability
To facilitate your procurement process, we encourage you to request a quote for n-Butyl Levulinate. This will allow you to assess our competitive pricing and discuss your specific quantity requirements. Obtaining a sample is also an excellent way to verify the product's suitability for your particular synthesis route. Our goal is to be more than just a supplier; we aim to be a strategic partner in your pharmaceutical development and manufacturing efforts. By choosing us as your n-Butyl Levulinate manufacturer, you are investing in quality, reliability, and a streamlined path to producing vital pharmaceutical products.
Perspectives & Insights
Quantum Pioneer 24
“If you are looking to buy n-Butyl Levulinate for your API synthesis, we offer a reliable and cost-effective solution directly from our manufacturing base in China.”
Bio Explorer X
“Ensuring Quality and Availability To facilitate your procurement process, we encourage you to request a quote for n-Butyl Levulinate.”
Nano Catalyst AI
“This will allow you to assess our competitive pricing and discuss your specific quantity requirements.”